Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $100000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $300000.0, a 93.76% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 97.58% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $100000.0, roughly flat from $100000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for AYTU reached as high as $2.7 million in Q1 2024 and fell as low as $100000.0 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $2.0 million in 2023.
• Across the five-year window, Depreciation & Amortization (CF) climbed 22.9% in 2024 and plunged 96.29% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.2 million in 2022, then declined by 18.81% to $1.8 million in 2023, then retreated by 25.24% to $1.3 million in 2024, then plunged by 92.53% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $100000.0 in Q1 2026, $100000.0 in Q4 2025, and $100000.0 in Q3 2025.